adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
pharma · Crohn's Disease · Ulcerative Colitis (UC)
AbbVie
AbbVie drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1 Waukegan Road, North Chicago, Illinois 60064, US HQ
60,084 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 1 Waukegan Road, North Chicago, Illinois 60064, US
- Employees
- 60,084
- Programs
- 0
- Drugs
- 25
- Patents
- 4
AbbVie pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AbbVie drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to AbbVie in public FDA and regional records.
-
botulinum toxin type a
Musculo-skeletal system (M03)Musculo-skeletal system (M03) compound in AbbVie's portfolio. Molecular target: Synaptosomal-associated protein 25.
- Target
- Synaptosomal-associated protein 25
- Mechanism
- Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
-
brimonidine
Dermatologicals (D11)Dermatologicals (D11) compound in AbbVie's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to AbbVie in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
cariprazine
Nervous system (N05)Nervous system (N05) compound in AbbVie's portfolio. Mechanism: Dopamine D3 receptor modulator.
- Mechanism
- Dopamine D3 receptor modulator
-
epcoritamab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AbbVie's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
glecaprevir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Hepatitis C virus serine protease, NS3/NS4A.
- Target
- Hepatitis C virus serine protease, NS3/NS4A
- Mechanism
- Hepatitis C virus serine protease, NS3/NS4A inhibitor
-
Development asset linked to AbbVie in public FDA and regional records.
-
Development asset linked to AbbVie in public FDA and regional records.
-
levodopa
Nervous system (N04)US regulatory status: approved. Molecular target: D(3) dopamine receptor.
- Target
- D(3) dopamine receptor
- Mechanism
- Dopamine D3 receptor agonist
-
Development asset linked to AbbVie in public FDA and regional records.
-
Development asset linked to AbbVie in public FDA and regional records.
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to AbbVie in public FDA and regional records. Molecular target: Folate receptor alpha.
- Target
- Folate receptor alpha
- Mechanism
- Folate receptor alpha binding agent
-
mirvetuximab soravtansine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AbbVie's portfolio. Molecular target: Folate receptor alpha.
- Target
- Folate receptor alpha
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to AbbVie in public FDA and regional records.
-
risankizumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in AbbVie's portfolio. Molecular target: Interleukin-23.
- Target
- Interleukin-23
- Mechanism
- Interleukin-23 inhibitor
-
ritonavir
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: Cytochrome P450 3A.
- Target
- Cytochrome P450 3A
- Mechanism
- Cytochrome P450 3A inhibitor
-
Development asset linked to AbbVie in public FDA and regional records. Molecular target: Hepatocyte growth factor receptor.
- Target
- Hepatocyte growth factor receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
upadacitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Tyrosine-protein kinase TYK2 inhibitor.
- Mechanism
- Tyrosine-protein kinase TYK2 inhibitor
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor